Park Medical Systems of Lachine, Quebec, has received the Foodand Drug Administration's go-ahead to market its Molecular CodedAperture Technology (MCAT), a collimator-based method for improvinggamma camera imaging at all energy levels.MCAT consists of
Park Medical Systems of Lachine, Quebec, has received the Foodand Drug Administration's go-ahead to market its Molecular CodedAperture Technology (MCAT), a collimator-based method for improvinggamma camera imaging at all energy levels.
MCAT consists of macro-collimators that attach to standard detectors,creating a coded pattern that is detected by the camera's photomultipliertube array. Software decodes the pattern into a high-resolutionimage covering a wide range of energies. Park believes the techniqueis more versatile than coincidence-detection methods for oncologyimaging.
Park will show the MCAT module, as well as clinical images, atthe Society of Nuclear Medicine meeting in San Antonio, TX, inJune.
Comparative AI Study Shows Merits of RapidAI LVO Software in Stroke Detection
February 6th 2025The Rapid LVO AI software detected 33 percent more cases of large vessel occlusion (LVO) on computed tomography angiography (CTA) than Viz LVO AI software, according to a new comparative study presented at the International Stroke Conference (ISC).
Study: Mammography AI Leads to 29 Percent Increase in Breast Cancer Detection
February 5th 2025Use of the mammography AI software had a nearly equivalent false positive rate as unassisted radiologist interpretation and resulted in a 44 percent reduction in screen reading workload, according to findings from a randomized controlled trial involving over 105,000 women.